Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Investor Day (October 2017)
128 slides from Fisher & Paykel Healthcare's investor day presentation, October 2017
Slide 1: Care by Design
Care by Design Fisher & Paykel Healthcare Investor Day Sydney, October 2017
Slide 2: Morning Agenda
Morning Agenda 10:00am Welcome Marcus Driller General Manager Corporate 10:00am Sustainable Profitable Growth Lewis Gradon Managing Director & CEO 10:15am Patient-focused R&D Andrew Somervell VP - Products & Technology 10:35am Sales Approach: Enabling Clinical Change Paul Shearer Senior VP - Sales &
Slide 3: Afternoon Agenda
Afternoon Agenda 1:00pm Building the body of clinical evidence for Chris Crone AIRVO R&D Manager myAirvo and Optiflow in the home 1:10pm Nasal high flow humidified air via Dr Darren Mansfield Monash Health hospital in the home 1:30pm Driving Patient Success with OSA Therapy Fiona Cresswell General M
Slide 4: Sustainable Profitable Growth
Sustainable Profitable Growth Lewis Gradon Managing Director & CEO
Slide 5: How long can you continue to grow at these kind of rates?
Question most often asked by investors How long can you continue to grow at these kind of rates? OPERATING REVENUE NZ$MILLIONS NET PROFIT AFTER TAX NZ$MILLIONS 5 YEAR CAGR = 12% 5 YEAR CAGR = 21%
Slide 6: We've established an enviable track record
We’ve established an enviable track record for delivering SUSTAINABLE REVENUE GROWTH.
Slide 7: Where will sustainable growth come from in the short-term?
Where will sustainable growth come from in the SHORT-TERM?
Slide 8: Where will sustainable growth come from in the medium-term?
Where will sustainable growth come from in the MEDIUM-TERM?
Slide 9: Where will sustainable growth come from in the longer-term?
Where will sustainable growth come from in the LONGER-TERM?
Slide 10: Our aspiration: Sustainably doubling
OUR ASPIRATION: Sustainably DOUBLING our constant currency revenue every 5-6 years.
Slide 11: Characteristics of our business
Characteristics of our business Market opportunities Barriers to entry • Diverse, growing clinical data • Regulated • Underpinned by favourable • Patented IP demographics, aging populations and • Care Continuum: Throughout hospital to developing country healthcare spend home • Sales force investment
Slide 12: Questions?
Questions?mm, | T= HEALTHCARE
Slide 13: Patient-focused R&D
Patient-focused R&D Andrew Somervell – Vice President Products and Technology
Slide 14: Improving Clinical Practice: R&D approach
Improving Clinical Practice: R&D approach • Unique products with valued differentiation that: − Improve care and outcomes − Lower overall cost of treating patients • Proven innovation history • Original thought required • Enabled through understanding unmet patient and caregivers’ needs
Slide 15: Patient Oriented R&D
Patient Oriented R&D • Philosophy of doing what’s best for the patient − Needs of all stakeholders align with patient needs − Encourages long term thinking − Ingrained in FPH culture • Patient focused multi-disciplinary product teams − Specialist skills, broad knowledge
Slide 16: Patient Focused Teams: In-depth Knowledge
Patient Focused Teams: In-depth Knowledge Physiology Key Opinion Leaders Environment Clinical Research Users Technology Adjacencies Competitors NEW IDEAS, ORIGINAL THOUGHT
Slide 17: Enabling our Product Teams
Enabling our Product Teams • Easy access to the user environment: − Strong relationships with local and offshore hospitals and homecare dealers − Patient knowledge, testing solutions • Learning by creating − Prototype, test, learn − World-class prototyping and testing facilities • Access to world-le
Slide 18: F&P 950: Redefining Expectations
F&P 950: Redefining Expectations • F&P 850 current market leader
Slide 19: AirSpiral Inspiratory Limb
AirSpiral Inspiratory Limb • Opportunity: − Optimal humidity, minimal condensation in difficult ambient conditions • Benefits: − Reduce ventilation breaks − Reduce infection risk − Reduce clinician’s time dealing with condensate • Idea: − Insulate delivered medical gas with pockets of air • Result:
Slide 20: Questions?
Questions?
Slide 21: Sales approach: enabling clinical change
Sales approach: enabling clinical change Paul Shearer Senior VP – Sales & Marketing
Slide 22: Clinical change process
Clinical change process C PRODUCT DEVELOPMENT FEEDBACK +) C a TRUSTED ADVISOR LONG COMPLEX SALES CYCLE Fisher &Paykel HEALTHCARE
Slide 23: Developing sales team effectiveness
Developing sales team effectiveness • Product training • Therapy understanding • Expert domain knowledge • Develop customer relationships • Trusted advisor Takes several years for a FPH sales rep to become fully effective Sales Therapy/ Products force Marketing Economics Evaluation Sales Adoption cl
Slide 24: Role of marketing
Role of marketing • Condition market for sales organisation • Patient group experts • Develop messaging and approach • Clinically-focused marketing • Promote FPH brand • Product approval and country registrations Sales Therapy/ Products force Marketing Economics Evaluation Sales Adoption clinical kn
Slide 25: Clinical and therapy validation
Clinical and therapy validation • Develop Key Opinion Leaders (KOL relationships) • Pilot studies • Physiological studies (Mechanisms) • Outcome studies (RCT) • Peer to peer education Sales Therapy/ Products force Marketing Economics Evaluation Sales Adoption clinical knowledge
Slide 26: Value-based economics
Value-based economics • Cost calculators • Translation of clinical evidence to financial benefits • User case studies • External financial validation • Reimbursement / payment pathways Sales Therapy/ Products force Marketing Economics Evaluation Sales Adoption clinical knowledge
Slide 27: Evaluation
Evaluation • Customer preparedness • Evaluation criteria • Educating clinicians over multiple shifts • Validating critical success factors • Trust and confidence Sales Therapy/ Products force Marketing Economics Evaluation Sales Adoption clinical knowledge
Slide 28: Sales achievement
Sales achievement • Contract (GPO / IDN) formularies • Win / meet tender specifications • Capital acquisition (annual cycles) • Lease / commitment programmes • Installation / in-service support • Customer success Sales Therapy/ Products force Marketing Economics Evaluation Sales Adoption clinical kn
Slide 29: Driving adoption
Driving adoption • Facilitate change management • Customer commitment • Standard of care • Physician-generated protocol • Product performance • Ongoing review Sales Therapy/ Products force Marketing Economics Evaluation Sales Adoption clinical knowledge
Slide 30: Customer satisfaction
Customer satisfaction • Proven product performance • Improved care and outcomes based on unique FPH product • Strong relationships and trust • Product standardisation and continuum of care • Customer commitment
Slide 31: Enabling clinical change - summary
Enabling clinical change - summary • Clinical change is a disruptive, lengthy and complex process • Clinicians: working with trusted products delivering improved outcomes to at risk patients are reluctant to change
Slide 32: Questions?
‘ Questions? Ly Fisher &Paykel HEALTHCARE
Slide 33: Airvo & Optiflow: World-Leading Technology
Airvo & Optiflow: World-Leading Technology Chris Crone Research & Development Manager – Airvo/Optiflow
Slide 34: What is Optiflow nasal high flow therapy?
What is Optiflow nasal high flow therapy? CONVENTIONAL NON-INVASIVE OXYGEN THERAPY VENTILATION
Slide 35: Interest accelerating in Nasal High Flow therapy
Interest accelerating in Nasal High Flow therapy Nasal High Flow 180 Clinical Papers 160 Published 140 Annually 120 100 80 60 40 20 0 2000 2002 2004 2006 2008 2010 2012 2014 2016 Adult Neonatal & Paediatric
Slide 36: 2014-2015: Breakthrough publications
2014-2015: Breakthrough publications
Slide 37: 2016: More evidence post-extubation
2016: More evidence post-extubation Summary - 7 centres in Spain - 527 patients at low risk of reintubation - Optiflow significantly reduced reintubation rates vs O2 Summary - 3 centres in Spain - 604 patients at high risk of reintubation - Optiflow was non-inferior to NIV Reintubation is linked wit
Slide 38: Emerging evidence in other areas
Emerging evidence in other areas • Hypercapnic patients − Large randomised controlled trials (RCTs) in planning stages (French government support) • Emergency department − Bell, et al. 2015. Emergency Medicine Australasia − Makdee, et al. 2017. Annals of Emergency Medicine • Wards − Pirret, et al. 2
Slide 39: Emerging evidence in other areas
Emerging evidence in other areas • Evolution in research − Different patient groups and settings − Larger trials • Towards: − All spontaneously breathing patients requiring respiratory support
Slide 40: FPH technology advantage
FPH technology advantage For Optiflow Nasal High Flow: • Generating with Airvo • Transporting with AirSpiral • Delivering with Optiflow Generating Transporting Delivering
Slide 41: Generating with Airvo
Generating with Airvo Superiority in: • Performance - humidification, flow, sensing • Versatility – wide range of temperatures, flows and oxygen • Mobility – throughout the hospital Generating Transporting Delivering
Slide 42: Transporting with AirSpiral
Transporting with AirSpiral • Superior protection against condensate • Patents filed on technology and processes Generating Transporting Delivering
Slide 43: Delivering with Optiflow
Delivering with Optiflow • The only interface with Evaqua technology • Reduces formation of mobile condensate • Comfort for patients and confidence for clinicians Delivering Generating Transporting Delivering
Slide 44: Exciting potential
Exciting potential • Huge clinical interest in Optiflow • We are well-positioned with Airvo, AirSpiral and Optiflow technologies
Slide 45: Questions?
Questions? | a) 33 a? . ae: = is wy
Slide 46: Transforming Respiratory Therapy in Infant Care
Transforming Respiratory Therapy in Infant Care Andy Niccol General Manager – Infant Care
Slide 47: Infant care continuum
Infant care continuum Resuscitation Invasive nCPAP Nasal Oxygen ventilation high flow therapy Fisher &Paykel HEALTHCARE
Slide 48: Current evidence supporting the clinical applications of NHF
Current evidence supporting the clinical applications of NHF
Slide 49: The next generation of care
The next generation of care 4A» & ‘ y Specifically designed for the delicate anatomy and flow requirements of your smallest patients. Optiflow” Junior 2 Fisher &Paykel HEALTHCARE
Slide 50: Enhanced prong retention
Enhanced prong retention — Allows for natural facial movement { when patient’s cheeks are compressed Optiflow” Junior 2 Waveflex’ Easier readjustment and } maintenance for caregivers TECHNOLOGY / Gd Optifiow™ Junior2 Fisher &Paykel HEALTHCARE
Slide 51: Enhanced prong retention
Enhanced prong retention Improves prong stability in the nostrils Wavefiex’” TECHNOLOGY Fisheré.Paykel HEALTHCARE
Slide 52: Wider range of sizes
range of sizes = ee XS ~ NEW ) APPROXIMATE AGE AND WEIGHT Age and weight information should only be used as ‘guide. Ensure dinical judgement is used when sizing. Weighty 05 1 2 25 Correlated age"* 28 2B BS OS wWhGA IGA WGA wKGA Welght (Kg)" 3 35 20 Correlated ago 375 40 56 WHGA—_WiGA a wiGh me ye ye
Slide 53: Retains existing product benefits
Retains existing product benefits
Slide 54: Wigglepads
Wigglepads — Fisher’ Paykel HEALTHCARE
Slide 55: Tube Technology
Tube Technology Fisher &Paykel HEALTHCARE
Slide 56: Questions?
. = O&, Questions?
Slide 57: Nasal High Flow: The Brisbane (Paediatric) Experience
Nasal High Flow The Brisbane (Paediatric) Experience Associate Professor Andreas Schibler Paediatric Intensive Care Staff Specialist FCICM - PICU Medical Lead of Paediatric Critical Care Research Group (PCCRG) Lady Cilento Children's Hospital and The University of Queensland The PCCRG receives an on
Slide 58: 2016: Current intubation rate <3%
2016: Current intubation rate <3%
Slide 59: Survey of NHF therapy use in Australia
Survey of NHF therapy use in Australia • 83 general paediatric departments (peripheral/secondary/tertiary) • 7/8 tertiary, 5/6 secondary and 38/69 peripheral response 50 • 45/49 use HFNC: 91% 45 Number of departments using 45 40 38 HFNC (of 49 total) 35 30 30 25 25 20 14 15 10 7 5 0 2010 2011 2012 2
Slide 60: Survey of NHF therapy use in Australia: Diagnostic groups
Survey of NHF therapy use in Australia Diagnostic groups • 100% of departments use it for bronchiolitis • 82% in pneumonia • 55% in reactive airways (asthma) • 40% in other respiratory disease
Slide 61: Other benefits of NHF therapy
Other benefits of NHF therapy • Can be applied very early in the disease process • Greater patient tolerance • Ease of application • Clinical effectiveness
Slide 62: What are the trials we need to do?
What are the trials we need to do? • RCT in infants with bronchiolitis • RCT in infants and children with Acute Hypoxic Respiratory Failure: - Pneumonia - Pneumonitis - Reactive Airway Disease (Asthma) When, Where and How? •Start in ED ? Early ? •Start only if admitted ? •Start only if certain sever
Slide 63: PaRIS
PaRIs Paediatric Acute Respiratory Intervention Studies High Flow Trial Children’s Health Queensland
Slide 64: PARIS Background
PARIS 1 Background Burden of Bronchiolitis •Highest number of non-elective PICU admissions in 2015 (19%). •Low mortality (~0%) •Median PICU LOS 3.08 days •Currently ANZPIC data registry showing higher figures for bronchiolitis admitted to ICU. Compatible with USA data which is also increasing. Is th
Slide 65: Mechanical Ventilation by Year
Mechanical Non-Invasive Year Ventilation Intubation Ventilation NHF therapy 2002 57.2% 36.6% 30.5% 2003 53.9% 30.9% 35.0% 2004 57.4% 29.2% 42.6% 2005 56.8% 29.5% 42.4% 2006 60.5% 26.9% 47.5% 2007 62.8% 26.5% 49.7% 2008 53.2% 23.5% 40.9% 2009 63.4% 25.9% 46.8% 2010 58.6% 24.5% 42.2% 24.7% 2011 62.0%
Slide 66: Modes of Respiratory Support in PICU for Bronchiolitis
Modes of Respiratory Support in PICU for Bronchiolitis
Slide 67: Health care costs associated with Bronchiolitis infants admitted to ICU
Health care costs associated with Bronchiolitis infants admitted to ICU
Slide 68: NHF introduction
NHF introduction Children’s Health Queensland ak) Rick
Slide 69: NHF = Everybody Loves it
NHF = Everybody Loves it Children’s Health Queensland ki Dik
Slide 70: NHF Everybody is over it
NHF Everybody is over it Children’s Health Queensland ki Dik
Slide 71: NHF Introduced in Paeds Ward
NHF Introduced in Paeds Ward Children’s Health Queensland ki Dik
Slide 72: NHF Reducing ICU admission
NHF Reducing ICU admission Children’s Health Queensland ki Dik
Slide 73: PARIS I – Nasal High Flow therapy in infants with bronchiolitis
PARIS I – Nasal High Flow therapy in infants with bronchiolitis – a Randomised Controlled Trial AIM To compare in a Randomised Controlled Trial, Nasal High Flow therapy to standard oxygen delivery in infants with bronchiolitis, presenting to regional, metropolitan and tertiary centres. PRIMARY OUTCO
Slide 74: Secondary Outcomes
Secondary Outcomes To measure: • reduction in the need for retrievals/ICU admission • reduction in intubation rate • reduction in LOS • length of oxygen therapy • adverse effects • health care costs • study effect of room air only?
Slide 75: Recruitment over 3 years – 1400 patients
Recruitment over 3 years – 1400 patients • Nine Regional Hospitals • Ipswich Hospital • Logan Hospital • TPCH • Nambour Hospital • Redcliffe Hospital • Toowoomba Hospital • Redland Hospital • The Tweed Hospital • Caboolture Hospital Additional PREDICT sites with NHMRC funding • LCCH • GCUH • RCH – M
Slide 76: Study Protocol
Primary Study Protocol Outcome n=1400 $1.3 M NHMRC funding Responder NHF Non-Responder Transfer 2L/kg/min Inclusion Criteria * Bronchiolitis * SpO2 <92/94%% Responder * < 12mths Control Responder NHF Non-Responder 2L/kg/min Non-Responder Criteria for non-responder: RR, HR and EWT unchanged after 120
Slide 77: Baseline Characteristics
Baseline Characteristics Standard Nasal High Oxygen Flow Sex N=731 N=745 Male 469 (64%) 455 (61%) female 261 (36%) 287 (39%) Median age months (IQR) months (IQR) 6.1 (3.4) 5.8 (3.5) Age ≤3 month 185 (25%) 207 (28%) 3-12 months 546 (75%) 538 (72%) Prematurity 107 (15%) 127 (17%) Weight (kg) (SD) 7.6
Slide 78: Primary Outcomes
Standard Nasal High P value Odds ratio Primary Outcomes Oxygen Flow N=731 N=745 Failure Rate 167 89 #0.0001 2.20 (1.65-2.89) % of patients 23% 12% Non- 55/130 28/179 #0.0001 2.71 (1.63-4.50) responders/Responders <3month of age Non- 112/434 61/477 #0.0001 2.02 (1.44-2.83) responders/Responders 3-12
Slide 79: PARIS II
P RIS Il Paediatric Acute Respiratory Intervention Studies Acute Hypoxemic Respiratory Failure AHRF Trial Children’s Health Queensland
Slide 80: AHRF Background
AHRF BACKGROUND • 6.3 million children < 5yrs died worldwide in 2013 (WHO) 1 million of these deaths - caused by resp infections • AHRF - most frequent reason for paeds admission Most common initial treatment is to offer 02 • Approx 20% of children with AHRF rapidly deteriorate and require assis
Slide 81: PARIS II Aim
PARIS II Nasal High Flow therapy in children with Acute Respiratory Failure – a Randomised Controlled Trial AIM To compare in a Randomised Controlled Trial, Nasal High Flow therapy to standard oxygen delivery in infants and children with Acute Hypoxemic Respiratory Failure (AHRF), presenting to regi
Slide 82: Secondary Outcomes
Secondary Outcomes To determine if use of NHF therapy reduces the need for hospital transfer to a tertiary centre To determine if there is an age dependent efficacy of NHF therapy To perform Subgroup Analysis for children with: eg. RAD (asthma), Bronchiolitis 12-24mths, Acute Lower Resp. Tract
Slide 83: Challenges PARIS 1 & 2 – Study specific
CHALLENGES PARIS 1 & 2 – Study specific • Bias (creep in effect) • If NHF therapy has been used prior in a centre (stronger bias present) • Adherence to protocol by medical staff – change in diagnosis to place child on NHF (bias) Consent Research culture present or not • Study Fatigue (PARIS 2 with
Slide 84: Thank you
THANK YOU
Slide 85: myAirvo Research Update
myAirvo Research Update Chris Crone Research & Development Manager – Airvo/Optiflow
Slide 86: Nasal High Flow - Acute vs. Chronic use
Nasal High Flow - Acute vs. Chronic use • Same therapy, different uses, different benefits Acute Chronic
Slide 87: Home-based clinical research
Home-based clinical research • More research being carried out in the home • Challenges − Patient group – age, care needs − Logistics − Compliance monitoring − Longer treatment times (1 year : 5 years) − Higher costs
Slide 88: Mechanisms research
Mechanisms research Author Journal Yr n Population Comparison F/up Effects Hasani 10 Bronchiectasis NHF vs no NHF 7d ↑ Increased Mucociliary clearance Chron Resp Dis 2008 Fraser 10 COPD NHF vs O2 <1d ↓ Reduced CO2 (measured through skin) 273 sleep studies in the Thorax 2016 ↓ Reduced Respiratory Rat
Slide 89: Outcomes research
Outcomes research Author Journal Yr n Population Comparison F/up Message Rea 108 COPD & NHF (w and w/o 1y Improved exacerbation days, time to 1st Resp Med 2010 Bronchiectasis O2) vs SC exacerbation, reduced antibiotic use Cirio 12 COPD in NHFO2 vs Venturi <1d Improved exercise tolerance Resp Med 201
Slide 90: COPD research underway
COPD research underway PI, Country n Population Comparison F/up Primary Outcome Weinreich, Denmark 200 COPD NHFO2 vs O2 1y Exacerbations & hospital admissions Mansfield, Australia 150 COPD NHF vs no NHF 30d Length of Stay, 30 d readmission Bräunlich, Germany 100 COPD NHF vs Bilevel 6w Capillary CO2
Slide 91: A bright outlook
A bright outlook • There are challenges to home-based research • Studies are underway with myAirvo and early results are promising
Slide 92: Questions?
a. WY Cc 2 om) WY ® =) 6)
Slide 93: Hospitalized COPD Exacerbations: Nasal High Flow Humidified Air via Hospital in the Home
HOSPITALIZED COPD EXACERBATIONS: NASAL HIGH FLOW HUMIDIFIED AIR VIA HOSPITAL IN THE HOME A/PROF DARREN MANSFIELD MONASH HEALTH
Slide 94: Disclosure
DISCLOSURE • A/Prof Mansfield has received research funding from Fisher & Paykel Healthcare. • Fisher &Paykel Healthcare will make a donation to the Monash Lung and Sleep Institute and Assoc Prof Mansfield will be reimbursed for any expenses incurred in connection with his participation in today’s e
Slide 95: The burden of disease on the acute facility
THE BURDEN OF DISEASE ON THE ACUTE FACILITY • COPD exacerbations Dandenong Hospital • 90% are admitted to hospital • No/yr • LOS 5.9 days • 60 day readmission rate 22% Large numbers due to comorbidities and social circumstances rather than severe acute exacerbations
Slide 96: Characteristics
CHARACTERISTICS FLOW RATES -60L/MIN TEMPERATURES 37 DEGREES LOOSE FITTING CANNULA
Slide 97: Postulated benefits
POSTULATED BENEFITS • Facilitative effects • Staff • Patients • Clinical/Physiological Effects
Slide 98: Respiratory
Respiratory Reduction of dead space =iovon Reduces rebreathing of gas with high CO, and depleted O2 Unassisted breathing Optiflow NHF TIDAL VOLUME TIDAL VOLUME Washout Dead space volume Dead space volume 1. Mandel T. et al. J App! Physiol. 2013. 2. Molier W. et al. Am J Respir Care Med. 2012. head
Slide 99: Preliminary numbers
PRELIMINARY NUMBERS • Admissions under Hospital In The Home (HITH) = 20 • Readmissions post discharge from HITH = 1 • Patients who purchased AIRVO system privately = 2 • Good outcomes in patient satisfaction with care & symptom improvement while on NHF
Slide 100: Summary
SUMMARY • Can realistically be incorporated into an acute clinical management setting • Reduces hospital length of stay, inpatient complications and recurrent admissions • Beneficial not only to patients • Can assist in unloading the healthcare system
Slide 101: Thank you
Thank you
Slide 102: Driving Patient Success with OSA Therapy
Driving Patient Success with OSA Therapy Fiona Cresswell General Manager Marketing
Slide 103: Unique and Personal
Unique and Personal Fisher &Paykel HEALTHCARE
Slide 104: The Threat
The Threat • Up to 100M OSA sufferers 1,2 • CPAP therapy is the gold standard of treatment • Up to 50% will abandon therapy, many within first 2 weeks • Untreated sleep apnea has many life threatening consequences 1. Chronic disease epidemics. World Health Organization website. May 23, 2012. 2. Pepp
Slide 105: Main Drivers of Non-Adherence
Main Drivers of Non-Adherence • Leaks 1 • Facial Abrasions 1 • Mask Discomfort 1,2 • Claustrophobia 1,2 1. Bollig, S.M. Respir Care, 2010. 55(9): pp. 1230-9 2. Aljasmi, M., et al. J Sleep Med Disord, 2016. 3(2): 1044
Slide 106: Intimacy of the Mask = Confidence
Intimacy of the Mask • Comfort • Seal • Ease of Use = CONFIDENCE
Slide 107: User Experience Mask Design Philosophy
User Experience Mask Design Philosophy Perception Fitting Seal Disassembly Cleaning Reassembly Confident ongoing use Patient Equipment Provider Perception Fitting Education Eliminates need Part identification for support & Resupply
Slide 108: Complex and Diverse Facial Anatomy
Complex and Diverse Facial Anatomy
Slide 109: Our Leading-Edge Masks
Our Leading-Edge Masks Eson”2 Brevida” Fisher &Paykel HEALTHCARE
Slide 110: AirPillow Seal
AirPillow Seal \ "| i Fisher & Paykel HEALTHCARE
Slide 111: We Measure What Nature Created
We Measure What Nature Created • Facial Scanning − Many hundreds of real OSA participants − 200,000+ points captured • Anthropometric Database − 42 key facial dimensions − Statistically analysed − Numerically driven seal design
Slide 112: We Use Technology to Optimise Design
We Use Technology to Optimise Design • 3D CAD Modelling ‒ Gradient transitions ‒ Integrated mask stabilizers • Massive Variable Thickness Moldings ‒ 1200% range in single molded part ‒ Satin surface finish
Slide 113: The Benefit
The Benefit 1 • Soft Nasal Prongs 2 ‒ 1/33 inch (0.75mm) thickness (1) ‒ Gently contours to nostril shape ‒ Significantly less pressure on the septum • Super Thin Silicone Seal Membrane ‒ Prongs surrounded by thin silicone ‒ 1/100 inch (0.25mm) thickness (2) ‒ Allows prong rotation in any direction
Slide 114: Adjustable Headgear
Adjustable Headgear Adjustable to offer Tactile Feedback and Provides stability personalised secure fit locks in place against dislodgement
Slide 115: We Consider Real World Use
We Consider Real World Use • Lifecycle Testing ‒ Soaked in sweat solution ‒ Cleaned over 50 times ‒ Stretched 2800 times • Destruction Testing ‒ Pulled until broken ‒ Target = 30N Force
Slide 116: Washable Exhaust Diffuser
Washable Exhaust Diffuser Fisher &Paykel HEALTHCARE
Slide 117: We Quantify the Invisible
We Quantify the Invisible • Sound Testing ‒ Target less than 25dBA • Draft Testing Anechoic Chamber
Slide 118: We Amplify Accuracy Using Technology
We Amplify Accuracy Using Technology • Computational Fluid Dynamics ‒ Map airflow ‒ Highlight turbulence ‒ Optimise design • Optical Gauge Smartscope ‒ Accuracy of 1.4µm
Slide 119: The Benefit
The Benefit • Reduced air flow disruption • Sound reduction - 17.5dB ‒ similar to a ticking watch
Slide 120: Visiblue
Visiblue • Blue Highlights incorporated into key components • Supports mask education, orientation and reassembly
Slide 121: F&P SleepStyle
F&P SleepStyle CPAP/Auto Therapy
Slide 122: Freedom in Simplicity
Freedom in Simplicity Easy-access User-friendly Chamber menu & buttons Built-in Quiet, integrated connectivity design options
Slide 123: Powered by Technology
Powered by Technology Auto Expiratory relief algorithm ThermoSmart™ SensAwake™
Slide 124: Engaging Patients
Engaging Patients Apple, the Apple logo and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. Google Play and the Google Play logo are trademarks of Google Inc.
Slide 125: Empowering Clinicians
Empowering Clinicians Fisher &Paykel HEALTHCARE
Slide 126: The Mask Matters Most
The Mask Matters Most y * Gia af (3
Slide 127: Questions?
Questions?
Slide 128: Thank you
Thank you Fisher & Paykel Healthcare Investor Day Sydney, October 2017
Fisher & Paykel Healthcare — Investor Day (October 2017) on 6ix